Recordati Confirms CVC Interest in Major Pharma M&A Deal
MILAN, Italy, March 26, 2026 Recordati S.p.A. has confirmed receiving a non-binding indication of interest from CVC Capital Partners...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
MILAN, Italy, March 26, 2026 Recordati S.p.A. has confirmed receiving a non-binding indication of interest from CVC Capital Partners...
MUMBAI, INDIA & NAPLES, USA | March 25, 2026 Lupin Limited, a global pharmaceutical leader, has received tentative approval...
Brussels, Belgium & Atlanta, Georgia – March 24, 2026 Strategic Biologics Expansion to Strengthen Global Supply In a major...
London, United Kingdom | March 23, 2026 The pharmaceutical industry is undergoing a profound transformation as artificial intelligence (AI),...
Florence, Italy – March 9, 2026 Menarini Group, one of Europe’s leading pharmaceutical companies, has reported strong financial growth...
